JP6389177B2 - オランザピンハプテンに対する抗体及びその使用 - Google Patents

オランザピンハプテンに対する抗体及びその使用 Download PDF

Info

Publication number
JP6389177B2
JP6389177B2 JP2015528596A JP2015528596A JP6389177B2 JP 6389177 B2 JP6389177 B2 JP 6389177B2 JP 2015528596 A JP2015528596 A JP 2015528596A JP 2015528596 A JP2015528596 A JP 2015528596A JP 6389177 B2 JP6389177 B2 JP 6389177B2
Authority
JP
Japan
Prior art keywords
antibody
group
olanzapine
formula
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015528596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529201A (ja
JP2015529201A5 (enExample
Inventor
リョホレンコ，エリック
サンカラン，バヌマティ
デコリー，トーマス，アール．
タブス，テレサ
コルト，リンダ
レメリー，バート，エム．
サルター，ライズ
ドナエ，マシュー，ギャレット
ゴング，ヨン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2015529201A publication Critical patent/JP2015529201A/ja
Publication of JP2015529201A5 publication Critical patent/JP2015529201A5/ja
Application granted granted Critical
Publication of JP6389177B2 publication Critical patent/JP6389177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
JP2015528596A 2012-08-21 2013-08-20 オランザピンハプテンに対する抗体及びその使用 Active JP6389177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691572P 2012-08-21 2012-08-21
US61/691,572 2012-08-21
PCT/US2013/055817 WO2014031656A1 (en) 2012-08-21 2013-08-20 Antibodies to olanzapine haptens and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153217A Division JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2015529201A JP2015529201A (ja) 2015-10-05
JP2015529201A5 JP2015529201A5 (enExample) 2016-04-28
JP6389177B2 true JP6389177B2 (ja) 2018-09-12

Family

ID=50148310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528596A Active JP6389177B2 (ja) 2012-08-21 2013-08-20 オランザピンハプテンに対する抗体及びその使用
JP2018153217A Active JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018153217A Active JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Country Status (11)

Country Link
US (3) US20140057303A1 (enExample)
EP (2) EP3581195B1 (enExample)
JP (2) JP6389177B2 (enExample)
CN (2) CN109400708A (enExample)
AU (3) AU2013305895B2 (enExample)
CA (1) CA2882595C (enExample)
ES (1) ES2733963T3 (enExample)
PL (1) PL2887952T3 (enExample)
PT (1) PT2887952T (enExample)
TR (1) TR201910347T4 (enExample)
WO (1) WO2014031656A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CN104736564B (zh) 2012-08-21 2019-02-05 詹森药业有限公司 喹硫平半抗原的抗体及其用途
CA2882595C (en) 2012-08-21 2019-06-04 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine haptens and use thereof
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PT3321254T (pt) 2012-08-21 2020-10-20 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
CN105601730A (zh) * 2014-10-30 2016-05-25 北京维德维康生物技术有限公司 呋喃妥因半抗原和抗原的制备方法及其在化学发光免疫试剂盒中的应用
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN114685527B (zh) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN119662553B (zh) * 2024-11-26 2025-11-28 江南大学 一种分泌奥氮平类化合物单克隆抗体的杂交瘤细胞株

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228A (en) 1849-03-27 Coejsr-shelleb
US4022780A (en) 1973-03-06 1977-05-10 Imperial Chemical Industries Limited Process for the manufacture of indole derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
CA2101337A1 (en) * 1991-02-01 1992-08-02 Stephan D. Glenn Method of producing f(ab')2 fragments of immunoglobulins
EP0517327B1 (en) 1991-06-07 2001-08-16 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay with labeled hapten analogues
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5616505A (en) * 1992-03-27 1997-04-01 Abbott Laboratories Haptens tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
ES2153373T3 (es) 1992-05-29 2001-03-01 Lilly Co Eli Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
AU710106B2 (en) 1994-06-10 1999-09-16 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
CN1646161A (zh) 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
EP2316469A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP2005533009A (ja) 2002-03-28 2005-11-04 イーライ・リリー・アンド・カンパニー ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
CA2494109A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US20040193446A1 (en) * 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
NZ543960A (en) 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
PT1664007E (pt) 2003-09-23 2010-02-15 Fermion Oy Preparação de quetiapina
BRPI0415165A (pt) 2003-10-01 2007-01-09 Adolor Corp composto heterocìclico espirocìclico, composição farmacêutica, método para ligar receptores opióides, métodos para prevenir ou tratar dor, disfunção gastrointestinal, um distúrbio do trato urogenital, um distúrbio imunomodulatório, um distúrbio inflamatório, um distúrbio de função respiratória, ansiedade, distúrbio do humor, um distúrbio relacionado a estresse, distúrbio do sistema nervoso simpático, tosse, e um distúrbio motor, método para tratar uma lesão traumática ao sistema nervoso central, métodos para prevenir ou tratar acidente vascular, arritmia cardìaca, glaucoma, e disfunção sexual, métodos para tratar uma condição selecionada do grupo consistindo de choque, edema cerebral, isquemia cerebral, déficit cerebral após cirurgia cardìaca (bypass) e enxerto, lupus eritematoso sistêmico, doença de hodgkin, doença de sjogren, epilepsia, e rejeição em transplantes de órgão e enxertos de pele, e para tratar dependência de substáncias, métodos para melhorar a sobrevivência de órgãos e células, e cardioproteção após infarto do miocárdio, métodos para reduzir a necessidade de anestesia, para produzir ou manter um estado anestésico, derivado radiomarcado de um composto, derivado isotopicamente marcado de um composto, composto e método de diagnóstico por imagem
WO2005059547A2 (en) 2003-12-12 2005-06-30 Inverness Medical Switzerland Gmbh Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
AU2008303540B2 (en) 2007-09-27 2012-04-26 Novartis Ag Drug monitoring assay
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
JP5828762B2 (ja) 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2010033270A1 (en) 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
EP2350077B1 (en) 2008-10-14 2016-01-27 Entasis Therapeutics Limited Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
EP2347015A4 (en) * 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
AU2010206376B2 (en) * 2009-01-26 2012-10-18 Egalet Ltd. Controlled release formulations with continuous efficacy
JP2012520073A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗原提示細胞ターゲティングワクチン
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
CA2777807A1 (en) * 2009-10-16 2011-04-21 Amic Ab An assay method and devices involving the use of magnetic particles
EP2519101B1 (en) 2009-12-31 2015-08-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
SI2544536T1 (sl) 2010-03-11 2019-03-29 Kempharm, Inc. Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CN102260290A (zh) 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
WO2011159537A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102276624B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
CN102276592B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2014028800A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
PT3321254T (pt) 2012-08-21 2020-10-20 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
CA2882595C (en) 2012-08-21 2019-06-04 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine haptens and use thereof
PL2888258T3 (pl) 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
PL2888257T3 (pl) 2012-08-21 2018-02-28 Janssen Pharmaceutica Nv Hapteny kwetiapiny do zastosowania w testach immunologicznych
ES2701062T3 (es) 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
CN104736564B (zh) 2012-08-21 2019-02-05 詹森药业有限公司 喹硫平半抗原的抗体及其用途
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL2888263T3 (pl) 2012-08-21 2018-10-31 Janssen Pharmaceutica Nv Hapteny rysperydonu i paliperydonu
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Also Published As

Publication number Publication date
JP2019004889A (ja) 2019-01-17
AU2013305895A1 (en) 2015-03-05
HK1211857A1 (en) 2016-06-03
AU2018200435A1 (en) 2018-02-08
US20170240653A1 (en) 2017-08-24
AU2019283807A1 (en) 2020-01-16
US20170343569A1 (en) 2017-11-30
CN109400708A (zh) 2019-03-01
AU2018200435B2 (en) 2019-09-19
TR201910347T4 (tr) 2019-07-22
WO2014031656A1 (en) 2014-02-27
CN104755093B (zh) 2018-11-16
US10712353B2 (en) 2020-07-14
JP6721641B2 (ja) 2020-07-15
CA2882595C (en) 2019-06-04
EP2887952A1 (en) 2015-07-01
CA2882595A1 (en) 2014-02-27
US20140057303A1 (en) 2014-02-27
JP2015529201A (ja) 2015-10-05
US11226345B2 (en) 2022-01-18
AU2013305895B2 (en) 2017-10-19
EP3581195B1 (en) 2025-10-01
PL2887952T3 (pl) 2019-11-29
EP3581195A1 (en) 2019-12-18
CN104755093A (zh) 2015-07-01
EP2887952A4 (en) 2016-04-13
AU2019283807B2 (en) 2021-04-29
EP2887952B1 (en) 2019-05-15
PT2887952T (pt) 2019-08-30
ES2733963T3 (es) 2019-12-03

Similar Documents

Publication Publication Date Title
JP6389177B2 (ja) オランザピンハプテンに対する抗体及びその使用
JP6389176B2 (ja) アリピプラゾールハプテンに対する抗体及びその使用
JP6637580B2 (ja) クエチアピンハプテンに対する抗体及びその使用
JP6971927B2 (ja) リスペリドンハプテンへの抗体及びその使用
JP6423490B2 (ja) オランザピン（Ｏｌａｎｚｉｐｉｎｅ）のハプテン
JP2018118972A (ja) パリペリドンハプテンに対する抗体及びその使用
HK40018877A (en) Antibodies to olanzapine haptens and use thereof
HK1211857B (en) Antibodies to olanzapine haptens and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170308

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20180517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389177

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250